Disruption of mutated BRAF signaling modulates thyroid cancer phenotype

BMC Research Notes

Volumn 7, Issue 1, 2014, Pages

  Hanly, Elyse K ^a   Rajoria, Shilpi ^a   Darzynkiewicz, Zbigniew ^a   Zhao, Hong ^a   Suriano, Robert ^a   Tuli, Neha ^a   George, Andrea L ^a   Bednarczyk, Robert ^a   Shin, Edward J ^b   Geliebter, Jan ^a   Tiwari, Raj K ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NEW YORK EYE AND EAR INFIRMARY   (United States)

Author keywords

BRAFV600E mutation; Kinase inhibitors; MAPK signal transduction pathway; PLX4032; Targeted therapy; Thyroid cancer

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; SULFONAMIDE; VEMURAFENIB;

CARCINOMA; CELL DEATH; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; THYROID CARCINOMA, ANAPLASTIC; THYROID GLAND; THYROID NEOPLASMS; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; CARCINOMA; CELL DEATH; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; PHENOTYPE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; SULFONAMIDES; THYROID CARCINOMA, ANAPLASTIC; THYROID GLAND; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84898483361     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-7-187     Document Type: Article

References (37)

1. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Chen AY, Jemal A, Ward EM, Cancer 2009 115 16 3801 3807 10.1002/cncr.24416 19598221
2. Increasing incidence of thyroid cancer in the United States, 1973-2002. Davis L, Welch HG, JAMA 2006 295 2164 2167 10.1001/jama.295.18.2164 16684987
3. The clinical and economic burden of a sustained increase in thyroid cancer incidence. Aschebrook-Kilfoy B, Schechter RB, Shih YC, Kaplan EL, Chiu BC, Angelos P, Grogan R, Cancer Epidemiol Biomarkers Prev 2013 Epub ahead of print
4. Thyroid carcinoma: molecular pathways and therapeutic targets. Nikiforov YE, Mod Pathol 2008 21 37 S43 18437172
5. BRAF mutation in papillary thyroid carcinoma. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D, J Natl Cancer Inst 2003 95 8 625 627 10.1093/jnci/95.8.625 12697856 (Pubitemid 36553510)
6. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA, Cancer Res 2003 63 1454 12670889
7. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinoho-Simoes M, Oncogene 2003 22 4578 4580 10.1038/sj.onc.1206706 12881714 (Pubitemid 36920701)
8. BRAF mutation in thyroid cancer. Xing M, Endocr Relat Cancer 2005 12 2 245 262 10.1677/erc.1.0978 15947100 (Pubitemid 40896444)
9. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P, Cancer Res 2009 69 21 8317 8325 10.1158/0008-5472.CAN-09-1248 19861538
10. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. Li C, Lee KC, Schneider EB, Zeiger MA, J Clin Endocrinol Metab 2012 97 12 4559 4570 10.1210/jc.2012-2104 23055546
11. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A, Vitale M, Journal Clin Endocrinol Metab 2012 6 7 2333 2340
12. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, et al. JAMA 2013 309 14 1493 1501 10.1001/jama.2013.3190 23571588
13. Roles of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehamnn B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA, Biochim Biophys Acta 2007 1773 8 1263 1284 10.1016/j.bbamcr.2006.10.001 17126425 (Pubitemid 47125967)
14. Guilty as charged: B-RAF is a human oncogene. Garnett MJ, Marais R, Cancer cell 2004 6 4 313 319 10.1016/j.ccr.2004.09.022 15488754 (Pubitemid 39361432)
15. Mutations of the BRAF gene in human cancer. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, et al. Nature 2002 417 949 954 10.1038/nature00766 12068308 (Pubitemid 34716871)
16. Inhibition of mutated, activated BRAF in metastatic melanoma. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB, New England Journal of Medicine 2010 363 809 819 10.1056/NEJMoa1002011 20818844
17. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, N Engl J Med 2011 364 2507 2516 10.1056/NEJMoa1103782 21639808
18. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring V600E BRAF mutation. Kim K, Cabanillas M, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ, Sherman SI, Thyroid 2013 Epub ahead of print
19. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R, Cell 2004 116 855 867 10.1016/S0092-8674(04)00215-6 15035987 (Pubitemid 38410730)
20. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF. Polikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N, Nature 2010 464 7287 427 440 10.1038/nature08902 20179705
21. Raf inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S, Nature 2010 464 7287 431 435 10.1038/nature08833 20130576
22. Laser scanning cytometry: a new instrumentation with many applications. Darzynkiewicz Z, Bedner E, Gorczyca W, Melamed MR, Exp Cell Res 1999 249 1 12 10.1006/excr.1999.4477 10328948 (Pubitemid 29394019)
23. Metastatic phenotype is regulated by estrogen in thyroid cells. Rajoria S, Suriano R, Shanmugam A, Wilson YL, Schantz SP, Geliebter J, Tiwari RK, Thyroid 2010 20 33 41 10.1089/thy.2009.0296 20067378
24. 3,3′-Diindolylmethane inhibits migration and invasion of human cancer cells through combined suppression of ERK and AKT pathways. Rajoria S, Suriano R, Wilson YL, Schantz SP, Moscatello A, Geliebter J, Tiwari RK, Oncol Rep 2011 25 491 497 21152869
25. Cytometry of DNA replication and RNA synthesis: Historical perspective and recent advances based on 'click chemistry. Darzynkiewicz Z, Zhao H, Halicka HD, Li J, Cytometry A 2011 79A 328 337 10.1002/cyto.a.21048
26. Key cancer cell signal transduction pathways as therapeutic targets. Bianco R, Melisi D, Ciardiello F, Tortora G, Eur J Cancer 2006 42 3 290 294 10.1016/j.ejca.2005.07.034 16376541 (Pubitemid 43132883)
27. Targeting cancer with small molecule kinase inhibitors. Zhang J, Yang PL, Gray NS, Nat Rev Cancer 2009 9 28 39 10.1038/nrc2559 19104514
28. Signal transduction therapy of cancer. Levitzki A, Klein S, Mol Aspects Med 2010 31 4 287 329 10.1016/j.mam.2010.04.001 20451549
29. Resistant mechanisms to BRAF inhibitor PLX3032 in melanoma. Curry JL, Falchook GS, Torres-Cabala C, Tetzlaff MT, Prieto VG, Expert Rev Dermatol 2011 6 4 355 357 10.1586/edm.11.38
30. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS, Nature 2010 468 7326 973 977 10.1038/nature09626 21107323
31. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G, J Clin Endocrinol Metab 2010 95 1 450 455 10.1210/jc.2009-0373 19880792
32. V600E inhibitor PLX4032(RG7204). Xing J, Liu R, Xing M, Trink B, Biochem Biophys Res Commun 2011 28 958 962
33. Vemurafenib: the first drug approved for BRAF-mutant cancer. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P, Nat Rev Drug Discov 2012 11 873 886 10.1038/nrd3847 23060265
34. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Sharma SV, Settleman J, Genes Dev 2007 21 24 3214 3231 10.1101/gad.1609907 18079171 (Pubitemid 350277749)
35. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M, Pigm Cell Melanoma R 2010 2 190 200
36. V600E inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. Liu R, Liu D, Xing M, J Clin Endocrinol Metab 2012 97 2 173 E182 10.1210/jc.2011-1054 22090271
37. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhbitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M, Ghossein RA, Rosen N, Fagin JA, Cancer Discov 2013 3 5 520 533 10.1158/2159-8290.CD-12-0531 23365119